Exchange: NYSEArca·Updated 07:41 PM EDT

VXF News

News
all
press releases
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.
Stocktwits
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.
Stocktwits
More News
GPUS Stock Slips After Hyperscale Data Carves Out Bitcoin Mining Business Into New Unit
Hyperscale Data management said Bitcoin mining and AI infrastructure require different capital strategies and priorities.
Stocktwits
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
Stocktwits
QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.
Stocktwits
Nakamoto CEO David Bailey Says Bitcoin’s Corporate Turn Isn’t A ‘Betrayal’ – Eyes Bigger Push Into M&A
David Bailey said Bitcoin’s corporate adoption is a part of its wider growth, as Nakamoto shifts toward M&A and cash-generating businesses.
Stocktwits
Should Vanguard Extended Market Index Fund ETF Shares (VXF) Be on Your Investing Radar?
Style Box ETF report for VXF
Zacks
Wall Street Believes SNOW's AI Demand Is Accelerating After Pre-Q2 Checks — Citizens Says 88% Of Data Points Are Positive
Analysts at UBS maintained their ‘Buy’ rating on Snowflake while raising their price target to $425 from $370, implying an upside potential of about 29% from Monday’s closing price.
Stocktwits
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’
Voyage is the company’s second successful late-stage readout for DT120, following positive results in major depressive disorder in June.
Stocktwits
DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data
Definium Therapeutics, which develops treatments for mental health conditions, faces high expectations for its late-stage Voyage study of DT120.
Stocktwits
HUBS Stock Heads Toward Worst Single-Day Fall In Over 10 Years — Wall Street Says HubSpot Is Headed To 'Penalty Box' Until Growth Improves
HubSpot's third-quarter outlook triggered a wave of analyst downgrades and price target cuts as Wall Street grew more cautious on demand.
Stocktwits

Advertisement|Remove ads.